Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
Study sponsor: ImmunityBio, Inc. · IBRX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-11Estimated
Enrollment · participants20Estimated
Source updated2025-10-16Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.